参芪抑瘤方含药血清对BGC-823胃癌细胞增殖和周期的影响

皮林君; 马春林; 李海龙; 曾庆涛; 刘佳楠; 吴红彦

doi:10.13422/j.cnki.syfjx.2018050121

您当前的位置：

首页 >

文章列表页 >

参芪抑瘤方含药血清对BGC-823胃癌细胞增殖和周期的影响

药理 | 更新时间：2024-01-04

- 参芪抑瘤方含药血清对BGC-823胃癌细胞增殖和周期的影响
- Effect of Serum Containing Shenqi Yiliu Prescription on Proliferation and Cycle of Gastric Cancer BGC-823 Cells
- 中国实验方剂学杂志 2018年24卷第5期页码：121-125
- 作者机构：
- 作者简介：
- 基金信息：
  
  国家自然科学基金项目（81660760）;兰州市人才创新创业扶持项目（2015-RC-24）
- DOI：10.13422/j.cnki.syfjx.2018050121
  中图分类号： R285
- 纸质出版日期：2018
- 稿件说明：
移动端阅览
皮林君, 马春林, 李海龙, 等. 参芪抑瘤方含药血清对BGC-823胃癌细胞增殖和周期的影响[J]. 中国实验方剂学杂志, 2018,24(5):121-125.

PI Lin-jun, MA Chun-lin, LI Hai-long, et al. Effect of Serum Containing Shenqi Yiliu Prescription on Proliferation and Cycle of Gastric Cancer BGC-823 Cells[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(5): 121-125.
皮林君, 马春林, 李海龙, 等. 参芪抑瘤方含药血清对BGC-823胃癌细胞增殖和周期的影响[J]. 中国实验方剂学杂志, 2018,24(5):121-125. DOI： 10.13422/j.cnki.syfjx.2018050121.

PI Lin-jun, MA Chun-lin, LI Hai-long, et al. Effect of Serum Containing Shenqi Yiliu Prescription on Proliferation and Cycle of Gastric Cancer BGC-823 Cells[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(5): 121-125. DOI： 10.13422/j.cnki.syfjx.2018050121.

摘要

目的：探讨参芪抑瘤方含药血清对胃癌细胞BGC-823增殖和周期的影响，并探讨其作用机制。方法：以参芪抑瘤方3%，5%，10%含药血清干预BGC-823细胞后，采用3-（4，5-二甲基噻唑-2）-2，5-二苯基四氮唑溴盐法检测其对细胞增殖的影响；采用流式细胞仪检测细胞周期变化；采用实时荧光定量PCR（Real-time PCR）检测细胞周期蛋白依赖性激酶（cyclin-dependent kinase inhibitor，CDKN）1B，CDKN1C mRNA表达；蛋白免疫印迹法（Western blot）检测p27，p57蛋白表达情况。结果：不同浓度含药血清作用于BGC-823细胞24，48，72 h后，细胞存活率显著降低（P<0.01），且与时间和浓度呈依赖关系；不同浓度含药血清作用于BGC-823细胞24 h后，G0/G1期细胞增多，S期细胞减少；Real-time PCR结果表明，与溶剂组和空白血清组比较，参芪抑瘤方各组CDKN1B，CDKN1C mRNA表达上调（P<0.05，P<0.01）；Western blot结果显示，与溶剂组比较，参芪抑瘤方各组p27，p57蛋白表达上调（P<0.05，P<0.01）。结论：参芪抑瘤方含药血清可以抑制胃癌BGC-823细胞的增殖，其机制可能通过调节CDKN1B，CDKN1C mRNA及p27，p57蛋白表达，进而干预细胞周期有关。

Abstract

Objective:To investigate the effect of serum containing Shenqi Yiliu prescription on inhibiting cell proliferation and blocking cell cycle of gastric cancer cell lines BGC-823

and explore its possible mechanism. Method:After being treated with 3%

5% and 10% serum containing Shenqi Yiliu prescription

gastric cancer cell lines BGC-823 were tested by 3-(4

5-dimethyl-2-thiazolyl)-2

5-diphenyl-2-H-tetrazolium bromide for proliferation; flow cytometry was used to detect the cell cycle; Real-time PCR technique was used to detect the mRNA expression of cyclin-dependent kinase inhibitor 1B (CDKN1B) and cyclin-dependent kinase inhibitor 1C (CDKN1C) genes; and Western blot was employed to test the protein expression levels of p27 and p57. Result:After 24

72 hours treatment with different concentrations of serum containing Shenqi Yiliu prescription

the cell viability was decreased significantly (P<0.01) in a time and dose dependent manner. Flow cytometry analysis showed

when treated by different concentrations of serum containing Shenqi Yiliu prescription for 24h

BGC-823 cells count in S phase was decreased significantly and increased in G0/G1 phase. Real-time PCR results showed

as compared with blank control group and solvent group

CDKN1B and CDKN1C mRNA expression levels were increased in each Shenqi Yiliu prescription group (P<0.05

P<0.01). Western blot results showed that as compared with blank control group

p27 and p57 protein expression levels were increased significantly in each Shenqi Yiliu prescription group (P<0.05

P<0.01). Conclusion:The serum containing Shenqi Yiliu prescription can inhibit the BGC-823 cell proliferation and the mechanism may be associated with regulating CDKN1B

CDKN1C mRNA and protein expression to intervene in the cell cycle.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

地参多糖对非小细胞肺癌A549细胞抗肿瘤作用及机制

回回甘松饮含药血清对大鼠肾小球系膜细胞增殖、周期及FN, Col11, Col41基因表达的影响

绞股蓝皂苷L影响GCK介导的糖酵解途径抗卵巢癌分子机制

中医药调控JAK/STAT信号通路干预肺癌的机制研究进展

中药调控JAK/STAT信号通路抗结直肠癌的研究进展